MX2019012648A - Radiolabeled (lys3) bn-ipsma for dual recognition of psma and grpr proteins in vivo. - Google Patents

Radiolabeled (lys3) bn-ipsma for dual recognition of psma and grpr proteins in vivo.

Info

Publication number
MX2019012648A
MX2019012648A MX2019012648A MX2019012648A MX2019012648A MX 2019012648 A MX2019012648 A MX 2019012648A MX 2019012648 A MX2019012648 A MX 2019012648A MX 2019012648 A MX2019012648 A MX 2019012648A MX 2019012648 A MX2019012648 A MX 2019012648A
Authority
MX
Mexico
Prior art keywords
grpr
psma
ipsma
lys3
vivo
Prior art date
Application number
MX2019012648A
Other languages
Spanish (es)
Inventor
García Blanca Elí Ocampo
Flores Guillermina Ferro
Castellanos Alondra Escudero
Gutiérrez Myrna Alejandra Luna
Cuevas Clara Leticia Santos
Mancilla Nallely Patricia Jimenez
Vega Erika Patricia Azorin
Original Assignee
Instituto Nac De Investigaciones Nucleares
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto Nac De Investigaciones Nucleares filed Critical Instituto Nac De Investigaciones Nucleares
Priority to MX2019012648A priority Critical patent/MX2019012648A/en
Priority to PCT/MX2019/000108 priority patent/WO2021080409A1/en
Publication of MX2019012648A publication Critical patent/MX2019012648A/en
Priority to ZA2022/05596A priority patent/ZA202205596B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Human prostate tumors show intrinsic heterogeneity and changes in phenotype during disease progression, implying different levels of expression of cell surface receptors. The present invention relates to a new radiolabeled (Lys3) Bombesin-iPSMA molecule for the dual recognition of PSMA (prostate specific membrane antigen) and GRPr (gastrin-releasing peptide receptor) proteins in vivo. Where the chemical-steric shielding of the radiometal chelating site promotes increased uptake and internalization in human prostate cancer cells. The new molecule (Lys3) Bombesin-iPSMA labeled with a radiometal (eg Lu-177), accumulates with high affinity in vivo in tumor cells that overexpress PSMA and / or GRPr proteins, acting as a heterodimeric radiopharmaceutical agent. The object of the present invention is to provide a new specific dual molecular recognition radiolabeled heterodimeric molecule (molecular target radiopharmaceutical) for the diagnosis and potential treatment of tumors with different expression levels of PSMA and GRPr.
MX2019012648A 2019-10-23 2019-10-23 Radiolabeled (lys3) bn-ipsma for dual recognition of psma and grpr proteins in vivo. MX2019012648A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
MX2019012648A MX2019012648A (en) 2019-10-23 2019-10-23 Radiolabeled (lys3) bn-ipsma for dual recognition of psma and grpr proteins in vivo.
PCT/MX2019/000108 WO2021080409A1 (en) 2019-10-23 2019-10-24 Radiolabelled (lys3)bn-ipsma for the dual recognition of the psma and grpr proteins in vivo
ZA2022/05596A ZA202205596B (en) 2019-10-23 2022-05-20 Radiolabelled (lys3)bn-ipsma for the dual recognition of the psma and grpr proteins in vivo

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2019012648A MX2019012648A (en) 2019-10-23 2019-10-23 Radiolabeled (lys3) bn-ipsma for dual recognition of psma and grpr proteins in vivo.

Publications (1)

Publication Number Publication Date
MX2019012648A true MX2019012648A (en) 2021-04-26

Family

ID=75620589

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012648A MX2019012648A (en) 2019-10-23 2019-10-23 Radiolabeled (lys3) bn-ipsma for dual recognition of psma and grpr proteins in vivo.

Country Status (3)

Country Link
MX (1) MX2019012648A (en)
WO (1) WO2021080409A1 (en)
ZA (1) ZA202205596B (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806806B2 (en) * 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
BR112019010947A2 (en) * 2016-11-30 2019-10-01 Univ Cornell ultra-small inhibitor functionalized nanoparticles and methods thereof

Also Published As

Publication number Publication date
WO2021080409A1 (en) 2021-04-29
ZA202205596B (en) 2023-01-25

Similar Documents

Publication Publication Date Title
Eder et al. Preclinical evaluation of a bispecific low‐molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer
Chatterjee et al. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors
Kuo et al. Effects of linker modification on tumor-to-kidney contrast of 68Ga-labeled PSMA-targeted imaging probes
Collingridge et al. The development of [124I] iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography
Tolmachev et al. Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry
Deyev et al. Comparative evaluation of two DARPin variants: effect of affinity, size, and label on tumor targeting properties
Malmberg et al. Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111 In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts
AU2020310538A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
Levi et al. A high-affinity, high-stability photoacoustic agent for imaging gastrin-releasing peptide receptor in prostate cancer
Summer et al. Cyclic versus noncyclic chelating scaffold for 89Zr-labeled ZEGFR: 2377 affibody bioconjugates targeting epidermal growth factor receptor overexpression
Carlucci et al. GRPR-selective PET imaging of prostate cancer using [18F]-lanthionine-bombesin analogs
MX2016008466A (en) 99mtc-edda/hynic-ipsma as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen.
Huang et al. Evaluation of 124I-JS001 for hPD1 immuno-PET imaging using sarcoma cell homografts in humanized mice
Malmberg et al. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In-and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody
Tang et al. A radiopharmaceutical [89Zr] Zr-DFO-nimotuzumab for immunoPET with epidermal growth factor receptor expression in vivo
EP2036576A1 (en) ED-B fibronectin as stratification marker for antitumor drugs
Zhang et al. Targeted radiotherapy with tumor vascular homing trimeric GEBP11 peptide evaluated by multimodality imaging for gastric cancer
Burvenich et al. Receptor occupancy imaging studies in oncology drug development
Lindbo et al. Optimized molecular design of ADAPT-based HER2-imaging probes labeled with 111In and 68Ga
Kim et al. Molecular imaging of colorectal tumors by targeting colon cancer secreted protein-2 (CCSP-2)
Altai et al. Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine
Marquez-Nostra et al. Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: Feasibility of an antibody-based companion diagnostic agent
Usmani et al. Neuroendocrine differentiation in castration resistant prostate cancer. Nuclear medicine radiopharmaceuticals and imaging techniques: A narrative review
MX2019012648A (en) Radiolabeled (lys3) bn-ipsma for dual recognition of psma and grpr proteins in vivo.
Martiniova et al. The role of radiolabeled monoclonal antibodies in cancer imaging and ADC treatment